CTOs on the Move

Eikon Therapeutics

www.eikontx.com

 
Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon`s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.eikontx.com
  • 3929 Point Eden Way
    Hayward, CA USA 94545
  • Phone: 341.777.0566

Executives

Name Title Contact Details
Russ Berman
Chief Technology Officer Profile
Ashish Kheterpal
Chief Information Officer Profile
John Shin
Director Information Technology Infrastructure Profile

Similar Companies

Molecular Assemblies

At Molecular Assemblies, we are enabling the next era in biotechnology through a completely new approach to DNA synthesis utilizing natural processes. We are developing a platform-independent, scalable DNA synthesis technology designed to produce long, high quality, sequence-specific DNA reliably, affordably and sustainably.

Sequenom

Sequenom is a leading high-performance DNA analysis company organized into two distinct business units:Sequenom Genetic Systems and Sequenom Pharmaceuticals.

Ignyta

Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases

Chiasma

Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.

Semler Research Center Pvt.

Semler Research Center Pvt. is a North Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.